Indeed, many studies have used high-dose recombinant GM-CSF as an adjuvant for peptide-based vaccines, and several cell-based cancer vaccine trials have used unprotected allogeneic cancer cells engineered to produce GM-CSF (GVAX platform [9, 10]). This evidence concerns the gene CSF2 and cancer.